Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GIPTRAP

Financiado

Cerrado

Therapeutic potential of recombinant antibodies to neutralize immunogenic peptid...

Therapeutic potential of recombinant antibodies to neutralize immunogenic peptides in celiac disease Celiac disease affects about 1% of the population worldwide. It is an autoimmune disease triggered by gluten intake in genetically predisposed individuals. Celiac disease causes intestinal villi atrophy that results in a deficient... ver más

31/12/2023

BIOMEDAL

161K€

Presupuesto del proyecto: 161K€

Líder del proyecto

BIOMEDAL Biotecnologia molecular, investigacion y diagnostico molecular agroalimentario y clinico. - se amplia objeto social de la sociedad de a los...

TRL 3-4 | 130K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

MSCA-IF-2020: Individual Fellowships Objective:The goal of the Individual Fellowships is to enhance the creative and innovative potential...

I+D

Cerrada hace 4 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BIOMEDAL

160.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 32 meses Fecha Inicio: 2021-04-16
Fecha Fin: 2023-12-31

Líder del proyecto

BIOMEDAL Biotecnologia molecular, investigacion y diagnostico molecular agroalimentario y clinico. - se amplia objeto social de la sociedad de a los...

TRL 3-4 | 130K€

Presupuesto del proyecto 161K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Celiac disease affects about 1% of the population worldwide. It is an autoimmune disease triggered by gluten intake in genetically predisposed individuals. Celiac disease causes intestinal villi atrophy that results in a deficient absorption of nutrients and other risks. Gluten major sources are wheat, rye, barley and some oats. Currently, the only effective treatment is a permanent gluten free diet (GFD). However, a fully GFD is difficult to achieve. The average daily gluten intake in celiac patients is estimated to be 150-400 mg, when 50 mg are enough to damage the intestine of most celiac patients. Accordingly, symptoms persist in 65% of patients, with only 8% reaching complete gut recovery. Preliminary data showed that an antibody raised against the most immunogenic gluten peptide suppressed 90% immunogenicity of hydrolyzed gluten ex vivo. This project proposes a novel therapeutic strategy to alleviate the effect of exposure to gluten for celiac patients not completely responsive to GFD. I aim to assess the potential of anti-Gluten Immunogenic Peptides (GIP) antibodies as therapeutic tools by evaluating their effectiveness to neutralize GIP in vitro and ex vivo. I will develop improved humanized recombinant versions of anti-GIP antibodies, analyze their performance and stability, and optimize their production in mammalian cell cultures in collaboration with partner biotech companies and academia research groups with long experience in the field, bringing novel transferable knowledge to the host institution. The recombinant antibodies will also be explored for their improved performance in diagnostic applications for determining GIP excretion. This Fellowship will allow to extend my existing network beyond Academia towards Biotech Industry and will provide me with significant experience to mature towards independent project management in industrial research in the fields of recombinant protein production and immunotherapy.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores